New Position to Focus on Acquisitions and Collaborations

LANCASTER, Calif.–Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of simulation and modeling software to the pharmaceutical industry, announces the appointment of Michael Pelekis, Ph.D., M.B.A., to the position of Director, Business Development.

Walt Woltosz, chairman and chief executive officer of Simulations Plus, said: “We’re extremely pleased that Michael has joined the Simulations Plus team. Michael comes to us with 20 years of experience in the pharmaceutical and environmental toxicology industries. Most recently he held the position of Principal Scientist with a top five pharmaceutical company. Michael holds both a Ph.D. in Pharmacokinetics and Toxicology as well as an MBA. His experience includes a broad spectrum of pharmaceutical and environmental research and development as well as business planning and strategy implementation, including serving as a research pharmacokineticist/toxicologist in the Toxicology Division of the Air Force Research Laboratory at Wright-Patterson AFB, Ohio. He’s an experienced user of Simulations Plus’ state-of-the-art GastroPlus™ and ADMET Predictor™ software programs, and has hands-on knowledge of other key pharmaceutical research software tools. We believe that Michael’s combination of pharmaceutical science knowledge and experience and his business management skills will serve Simulations Plus well as we look to accelerate our continued growth in the coming months and years.”

Dr. Pelekis added: “I’m excited about becoming part of the Simulations Plus team and contributing to the growth of the company. I think my background and experience in both the science and business sides of the pharmaceutical industry is a great fit with the new business development role here at Simulations Plus. In particular, my work in simulation and modeling, for which I’ve long had a passion, should be important in helping form profitable collaborative efforts and acquisitions.”

About Simulations Plus, Inc.

Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation and modeling software, which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide. The Company has two other businesses, Words+, Inc. and FutureLab™, which are based on its proprietary software technologies. Simulations Plus, Inc., is headquartered in Southern California. For more information, visit our web site at www.simulations-plus.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. The actual future results of the Company could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: the ability of the Company to maintain its competitive advantage, the general economics of the pharmaceutical and assistive technology industries, the ability of the Company to attract and retain sufficient scientific and technical staff to sustain its R&D and customer support functions, the continued high renewal rate for the Company’s software licenses, and a sustainable market. Further information on the Company’s risk factors is contained in the Company’s quarterly and annual reports as filed with the Securities and Exchange Commission.